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ABSTRACT
Introduction: Adverse events and
complications limit the long-term use of
current antidiabetic treatment options for
patients with type 2 diabetes mellitus (T2DM),
particularly for older adults who are often
receiving therapy for other comorbid
conditions. The aim of this study was to
evaluate the benefits of the dipeptidyl
peptidase-4 inhibitor, alogliptin, versus
glipizide, a sulfonylurea, in achieving glycemic
control without the risk of hypoglycemia,
weight gain, or both in older patients with
T2DM.
Methods: This was an exploratory, post hoc
analysis of a global, multicenter, randomized,
double-blind, active-controlled study
comparing alogliptin and glipizide. Patients
(n = 441) aged 65–90 years with glycosylated
hemoglobin (HbA1c) 6.5–9.0% who failed on
diet and exercise alone or who had inadequately
controlled T2DM despite oral antidiabetic
monotherapy were recruited from 110 sites
across 15 countries. Alogliptin 25 mg (n = 222)
or glipizide 5 mg up-titrated to 10 mg (n = 219)
was administered once daily for 52 weeks.
Composite endpoints of HbA1c B7.0% coupled
with the absence of hypoglycemia and weight
gain, or an HbA1c reduction of C0.5% in the
absence of hypoglycemia and weight gain, were
then measured.
Results: In the primary analysis, least squares
mean HbA1c changes from baseline to Week 52
were similar in both the alogliptin and glipizide
groups. The proportion of patients achieving
HbA1c B7.0% without hypoglycemia or weight
gain was significantly higher for alogliptin
versus glipizide (24% vs 13%, p\0.03).
Patients with a baseline HbA1c of\8.0%
receiving alogliptin were also more likely to
achieve HbA1c B7.0% without hypoglycemia or
weight gain than those receiving glipizide (29%
vs 13%, p\0.03).
Trial registration: ClinicalTrials.gov #NCT00707993.
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Conclusion: Alogliptin demonstrated similar
efficacy to glipizide in lowering HbA1c in
older patients with T2DM, but with
significantly more patients achieving an
HbA1c B7.0% without hypoglycemia or an
increase in body weight. These results
particularly apply to patients with baseline
HbA1c below 8.0%.
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is very
common in older individuals. Indeed, US data
from the Centers for Disease Control and
Prevention in 2011 showed that the
percentage of diagnosed diabetes was more
than 13 times higher in people aged
65–74 years when compared with those
younger than 45 years of age; the overall
percentages for these two populations were
reported to be 21.8% and 1.6%, respectively
[1]. Furthermore, the most recent International
Diabetes Federation Diabetes Atlas estimates
that the global burden of diabetes in older
individuals will increase greatly by 2030
(between 42% and[50%) in people over the
age of 60 [2].
There are a number of treatment options
available for patients with diabetes; however,
many of them are associated with significant
clinical adverse events (AEs). Metformin, which
is considered the standard initial therapy for
T2DM in conjunction with diet and exercise
regimens [3], is associated with gastrointestinal
AEs and, rarely, lactic acidosis [4]. It is also
contraindicated in patients with compromised
renal function: the package insert states that
metformin treatment ‘‘should not be initiated
in patients C80 years of age unless
measurement of creatinine clearance
demonstrates that renal function is not
reduced’’ [4], which is a common comorbid
condition in older patients. Moreover, serum
creatinine levels may be unreliable in an older
patient with low muscle mass. Similarly,
sulfonylureas, which are often prescribed as an
initial therapy in patients who are not
overweight, or as an additional therapy in
patients who have failed to achieve adequate
glycemic control with metformin alone, are
associated with hypoglycemia and weight gain
[3]. Hypoglycemia is of particular importance in
older patients because drug-induced
hypoglycemic episodes may go unrecognized
and may be confounded by cognitive
dysfunction. Hypoglycemic episodes are more
common and often more serious in older
patients receiving oral antidiabetic drugs and
can lead to complications such as falls and hip
fractures, as well as even more serious
cardiovascular events and death [5, 6]. These
AEs and complications all limit the long-term
use of sulfonylureas. This is particularly true in
older adults who often have underlying health
problems and may also be receiving treatment
for other comorbid conditions.
Alogliptin is a dipeptidyl peptidase-4 (DPP-4)
inhibitor that has shown efficacy as a treatment
for T2DM, either as monotherapy in
conjunction with diet and exercise or as an
adjunct therapy to other diabetic treatments
such as sulfonylureas, metformin,
thiazolidinediones, or insulin [7–11]. In
particular, in an exploratory retrospective
pooled analysis of one phase 2 and five phase
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3 studies, alogliptin was shown to be
consistently efficacious and demonstrated a
good safety profile in patients aged between 65
and 80 years. These benefits were seen when
alogliptin was administered both as
monotherapy and as an add-on therapy, and
was not found to increase the incidence of
hypoglycemia, weight gain, or other AEs when
compared with younger patients [6].
In this exploratory, post hoc analysis of a
prospective study specifically designed to
evaluate the efficacy of alogliptin and
glipizide, a sulfonylurea, we focused on
patients aged 65–90 years over a 52-week
period [12]. The purpose of the study was to
explore the benefits of alogliptin in achieving
glycemic control without the risk of weight
gain, hypoglycemia, or both, as compared with




This study was an exploratory post hoc analysis
of data obtained from a global, multicenter,
randomized, double-blind, active-controlled
study (NCT 00707993) that evaluated the
efficacy and safety of alogliptin versus glipizide
in patients with T2DM between the ages of 65
and 90 years. Patients were recruited from 110
sites across 15 countries. To be included patients
must have failed on diet and exercise alone in
the 2 months prior to screening and had
glycosylated hemoglobin (HbA1c) of 6.5–9.0%
or had inadequately controlled T2DM
(HbA1c 6.5–8.0%) despite oral antidiabetic
monotherapy, which had to be washed out
during the lead-in period. Patients must have
been able and willing to self-monitor blood
glucose with a home glucose monitor [12].
Patients were included in a screening period
of up to 2 weeks followed by a 52-week
treatment period. At Week 52, patients
underwent an end-of-study visit and a follow-
up visit 2 weeks later. Treatment-naı¨ve patients
were immediately randomized while patients
who had received oral monotherapy underwent
a 4-week washout period and were randomized
if their HbA1c level was between 6.5% and 9.0%
without antidiabetic medication [12].
Patients were randomized to receive
alogliptin (25 mg) or glipizide (5 mg) once
daily. Glipizide could be titrated from 5 to
10 mg in patients with persistent
hyperglycemia. Post-titration dose reductions
were allowed only once, mainly for
hypoglycemia. Patients who continued to be
hyperglycemic while receiving either study drug
were administered rescue medication according
to increasingly stringent rescue criteria once
elevated fasting plasma glucose or HbA1c was
confirmed [12].
The analysis in this article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors. The
original study was performed in accordance
with the Declaration of Helsinki, the
International Conference on Harmonisation’s
Harmonised Tripartite Guideline for Good
Clinical Practice, and all applicable regional
laws and regulations. An institutional review
board or ethics committee conducted the initial
approval and continuing review of the study
and all patients signed an informed consent
form prior to undergoing any procedures.
Composite Endpoints
The primary endpoint for the initial study was
HbA1c changes at Week 52 from baseline using
the last observation carried forward and the per-
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protocol set, consisting of all randomized and
treated patients with no major protocol
violations. Secondary endpoints included
changes from baseline in HbA1c at all time
points and by baseline HbA1c, fasting plasma
glucose, 2-h postprandial glucose,
hyperglycemic rescue, and weight and lipid
changes over time [12].
In this exploratory analysis, the composite
endpoint of HbA1c B7.0% coupled with the
absence of hypoglycemia and no body weight
gain was analyzed. HbA1c reduction of C0.5%
coupled with the absence of hypoglycemia and
no weight gain was also assessed. All randomized
and treated patients were used for these analyses.
Hypoglycemic events were rigorously captured
and identified using the stringent American
Diabetes Association (ADA) Workgroup on
Hypoglycemia-specified criteria of\70 mg/dL
(3.9 mmol/L) [13]. Patients were provided with
explicit instructions regarding the signs and
symptoms of hypoglycemia at study entry.
They then received diaries and blood glucose
meters to self-report hypoglycemic episodes by
recording glucose values and associated signs
and symptoms. All glucose measurements were
stored on the glucose meters, downloaded by the
study personnel and included as part of the
overall hypoglycemia evaluation. Hypoglycemic
episodes were defined as plasma glucose below
70 mg/dL (3.9 mmol/L) and were categorized
as mild to moderate (symptomatic or
asymptomatic) or severe (any episode requiring
assistance from another person to actively
administer carbohydrate, glucagon, or other
resuscitative actions, regardless of whether
plasma glucose was obtained).
Safety
Safety variables assessed in the original clinical
study [12] included pretreatment events, AEs,
clinical laboratory tests (hematology, serum
chemistry, and urinalysis), vital sign
measurements, physical examination findings,
and 12-lead electrocardiography readings.
Statistics
All statistical analyses were performed in those
who completed the study using SAS version 8.2
or higher (SAS Institute, Cary, NC, USA).
Participants without a Week 52 HbA1c or
weight value were treated as failures for the
composite endpoints. All statistical tests were
conducted at a 5% significance level.
The composite endpoints were analyzed
overall, irrespective of baseline HbA1c, using
logistic regression models with a factor for
treatment (alogliptin or glipizide) and with
baseline HbA1c and baseline weight as
covariates. Additional logistic regression
models were fitted separately for patients with
a baseline HbA1c\8.0% and C8.0%.
RESULTS
Disposition, Demographics, and Baseline
Characteristics
The patient disposition of this population is
shown in Fig. 1. A total of 441 patients were
randomized: 222 patients to the alogliptin
group and 219 to the glipizide group. In the
alogliptin group, 60% completed the study,
25% received hyperglycemia rescue, and 15%
discontinued for other reasons. In the glipizide
group, the equivalent percentages were 57, 22,
and 22%, respectively. The mean age of the
total population was 69.6 years and the mean
baseline HbA1c was 7.5%.
Patient demographics and baseline
characteristics in the Randomized Set are
described in Table 1. Overall, the patients in
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the alogliptin and glipizide groups were well
matched for demographics and baseline
characteristics. The majority of patients
(approximately three-fourths in each group) had
a baseline HbA1c of\8.0%. Themean ± standard
deviation (SD) body weights in the alogliptin
and glipizide groups were 78.6 ± 14.8 kg and
78.8 ± 15.2 kg, respectively, with mean ± SD
body mass index values of 29.6 ± 4.4 kg/m2 and
30.0 ± 4.5 kg/m2, respectively.
Glycemic Control
The results from the primary analysis in the
original clinical study [12] showed that the least
squares (LS) mean changes in HbA1c from
baseline to Week 52 were similar between
alogliptin and glipizide (Fig. 2). Indeed, the
reduction from baseline in LS mean observed
HbA1c values was similar for both the alogliptin
and glipizide groups throughout the 52-week
study (Fig. 2).
An exploratory analysis of the per-protocol
set, conducted in the primary study [12], revealed
larger reductions in HbA1c among patients who
completed the study (-0.47% and -0.31% with
alogliptin and glipizide, respectively) than
among rescued patients (0.61% and 0.53% with
alogliptin and glipizide, respectively). Similarly,
greater HbA1c reductions occurred among drug-
naı¨ve patients (-0.32% and -0.12% with
alogliptin and glipizide, respectively) than
among the 45.6% of monotherapy patients who
entered the study after a 4-week washout (0.09%
and -0.03% with alogliptin and glipizide,
respectively).
Fig. 1 Patient disposition of the study population (adapted
from Rosenstock et al. [12]). a‘‘Hyperglycemic rescue’’ and
‘‘discontinued’’ were mutually exclusive groups. Participants
who met the prespeciﬁed hyperglycemia rescue criteria and,
thus, discontinued treatment due to lack of efﬁcacy were
not included in the number of participants who discon-
tinued therapy. AE adverse event
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Composite Endpoints
A significantly greater proportion of all patients
in the alogliptin group achieved an HbA1c
of B7.0% without hypoglycemia and weight
gain compared with the glipizide group
(Figs. 3, 4). Similar results were also observed
when an HbA1c decrease of C0.5% was assessed,
although the difference did not reach statistical
significance (Figs. 3, 4). In the cohort of patients
with baseline HbA1c\8.0%, significantly higher
percentages of patients in the alogliptin group
achieved the target HbA1c of B7.0% and an
HbA1c decrease of C0.5%, both coupled with a
lack of hypoglycemia and weight gain,
compared with the glipizide group (Figs. 3, 4).
Similar numbers of participants in the alogliptin
and glipizide groups with baseline HbA1c C8.0%
achieved the composite endpoints (Figs. 3, 4).
Safety
Full safety results from the original study have
been reported previously [12]. In brief, a total of
314 patients (71.2%) experienced one or more
AEs. Most individual AEs occurred in fewer than
1% of patients overall. The most common AE
associated with alogliptin was headache (2.7%,
Table 1 Patient disposition, demographics and baseline





Study populations, n (%)
Safety set 222 (100) 219 (100)
Per-protocol set 180 (81) 162 (74)
Geographic region, n (%)
North America 62 (28) 65 (30)
Latin America 59 (27) 54 (25)
Europe, rest of the world 101 (46) 100 (46)
Baseline HbA1c, n (%)
\8.0% 168 (76) 170 (78)
C8.0% 54 (24) 49 (22)
Sex, n (%)
Male 102 (46) 96 (44)
Age







\75 years, n (%) 186 (84) 193 (88)
C75 years, n (%) 36 (16) 26 (12)
Race, n (%)
American Indian or Alaskan
Native
12 (5) 13 (6)
Asian 19 (9) 26 (12)
Black or African American 16 (7) 20 (9)
White 169 (76) 154 (70)
Multiracial 6 (3) 6 (3)
Mean ± SD weight, kg 78.6 ± 14.8 78.8 ± 15.2
Mean ± SD BMI, kg/m2 29.6 ± 4.6 30.0 ± 4.5
Mean ± SD diabetes
duration, years
6.25 ± 6.3 5.94 ± 6.3









Mean ± SD GFR, mL/min/1.73 m2
MDRD 74 ± 15 73 ± 16
Cockcroft–Gault 78.3 ± 18 78 ± 20
BMI body mass index, GFR glomerular ﬁltration rate,
HbA1c glycosylated hemoglobin, MDRD Modiﬁcation of
Diet in Renal Disease, SD standard deviation
a Evaluated using all randomized and treated participants
with available HbA1c data after baseline
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with the same incidence also being reported for
glipizide). Hypoglycemia and dizziness were the
most common glipizide-associated AEs, with
3.7% of patients in the glipizide group reporting
each of these events versus 0% and 0.9% in the
alogliptin group, respectively.
DISCUSSION
Alogliptin demonstrated similar efficacy to
glipizide in lowering HbA1c in this older
population of patients with T2DM, as
previously reported in the original clinical
study [12]. This exploratory analysis has
extended the data from the original study and
demonstrated that significantly more patients
in the alogliptin group achieved an HbA1c goal
of B7.0% without hypoglycemia and weight
gain when compared with the glipizide group.
In general, in this older population of patients
with T2DM, alogliptin was well tolerated and
acceptably safe with significantly less
hypoglycemia compared with glipizide; full
tolerability data have been reported previously
[12].
The assessment of HbA1c is a vital part of the
clinical assessment of glycemic control. Most
guidelines recommend a target HbA1c of 7.0%,
but emphasize the need to individualize
treatment targets, especially in older patients
with comorbidities [14]. Assessing other clinical
outcomes, particularly safety, alongside HbA1c
Fig. 2 Mean change in HbA1c ± SE (observed and
primary endpoint) from baseline to Week 52 in the per-
protocol set. HbA1c glycosylated hemoglobin, LS least
squares, SE standard error. Figure adapted from Rosen-
stock et al. [12]
Fig. 3 Number of participants who achieved the compos-
ite criteria of no hypoglycemia and weight gain with either
an HbA1c of B7.0% or an HbA1c decrease of C0.5% in
a all patients, b patients with HbA1c\8.0%, and
c patients with HbA1c C8.0%. *p\0.03 alogliptin versus
glipizide. HbA1c glycosylated hemoglobin
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is now recognized as an important part of the
personalized management of T2DM [14].
Indeed, the use of a patient-centered approach
for the treatment of patients with chronic
diseases is one of the key factors in evidence-
based medicine. This approach takes into
consideration individual patient preferences,
needs and values [3]. It is particularly
appropriate for patients with T2DM, especially
older patients who often have comorbid
conditions that are contraindicated for certain
treatment options.
The extent to which HbA1c levels should be
corrected in elderly patients is still in question.
Data from three short-term studies, the Action
to Control Cardiovascular Risk in Diabetes
(ACCORD) [15], the Action in Diabetes and
Vascular Disease: Preterax and Diamicron
Modified-Release Controlled Evaluation
(ADVANCE) [16], and the Veterans Affairs
Diabetes Trial (VADT) [17], have shown no
reduction in primary cardiovascular endpoints
with tight glycemic control when compared
with standard glycemic control in older
patients. Indeed, the ACCORD study showed a
22% increase in total mortality with the
intensive therapy regimen in patients aged
40–79 years. The cause of the unchanged or
even negative effect of intensive therapy on
cardiovascular endpoints is unclear but older
age is a risk factor for severe hypoglycemia [18],
and older patients are at greater risk of
hypoglycemia-associated morbidity, which
could be a contributory factor [19]. This
increased risk of severe hypoglycemia is
thought to be due to a combination of age-
Fig. 4 Odds ratios for achieving the composite criteria of
no hypoglycemia and weight gain with either an HbA1c
of B7.0% or an HbA1c decrease of C0.5% with alogliptin
versus glipizide. CI conﬁdence interval, HbA1c glycosylated
hemoglobin
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related comorbid conditions present in this
population as well as a lack of awareness of
the symptoms of hypoglycemia, such as
cognitive dysfunction, weakness, and
unsteadiness, which are often mistaken for
other conditions. Hypoglycemia in this
population can lead to significant morbidity,
including serious vascular events such as stroke
and myocardial infarction [19]. Therefore,
avoiding—or at least reducing—hypoglycemia
risk in the older patient is particularly
important and will impart significant clinical
benefits. Indeed, the importance of avoiding
hypoglycemia in the elderly is uniformly
recognized as a key feature in the treatment of
this patient population. The recently updated
Canadian Diabetes Association (CDA)
guidelines recognize the importance of
hypoglycemia avoidance over achieving
glycemic targets in some elderly patients,
including those who are frail or demonstrate
cognitive impairment [20]. These guidelines
suggest that, in these patients, sulfonylureas
should be used with caution, further
highlighting the need for individualized
treatments.
Weight gain has been associated with
increased cardiovascular risk in patients with
T2DM and is, therefore, another important
clinical outcome that should be carefully
controlled [21]. The benefits of DPP-4
inhibitors in terms of weight neutrality and no
increased risk of hypoglycemia have been
recognized in the recent position statement
published by the ADA and the European
Association for the Study of Diabetes (EASD)
[3]. The use of composite analyses, such as the
ones used in this exploratory study, allows for
the assessment of more than 1 clinically
relevant outcome. This is important in the
decision-making process for selecting
treatment options for T2DM, particularly in
the older patient, because often there is a need
to focus on and consider more than 1
therapeutic goal. A number of studies
comparing the efficacy of DPP-4 inhibitors and
sulfonylureas on composite outcomes,
comprising HbA1c targets, without
hypoglycemia or weight gain have now been
published. Similar to the results found in the
current analysis, sitagliptin and saxagliptin, in
addition to metformin, were found to result in
more adult patients with T2DM achieving
HbA1c targets without hypoglycemia or
weight gain compared with glipizide [22, 23].
Vildagliptin and linagliptin have also been
shown to help more T2DM adult patients
inadequately controlled with metformin reach
a composite endpoint of HbA1c\7.0% with no
hypoglycemia and no weight gain when
compared with another sulfonylurea,
glimepiride [24, 25]. Although these studies
were all performed in adult patients and were
not specifically conducted in older patient
cohorts, one study [24] that examined the
effectiveness of antidiabetic drugs in different
age groups found that vildagliptin was superior
to glimepiride in achieving an HbA1c target
of\7.0% with no hypoglycemia and no weight
gain in patients of all ages, including those aged
60 to\70 and 70 to\80 years.
In our original study [12], alogliptin and
glipizide resulted in similar reductions in HbA1c
at Week 52 from baseline using the last
observation carried forward (the primary
endpoint), as well as reductions in observed
HbA1c values throughout the 52-week period.
However, in both groups, reductions from
baseline to Week 52 in the primary endpoint
were only small; a finding that was not
predicted. In an exploratory analysis
performed on the data from the per-protocol
set in the original study, a comparison between
patients who completed the study and those
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who received rescue medication was performed
[12]. This analysis found that while patients
who completed the study (i.e., who did not
receive rescue medication) demonstrated
reductions in HbA1c within the magnitude
expected with alogliptin or glipizide, those
who did receive rescue medication actually
showed an increase in HbA1c levels. Therefore,
it would appear that the inclusion of rescued
patients, with the last observation carried
forward, may have been a contributing factor
to the unexpectedly small reductions in HbA1c
from baseline to Week 52 [12]. A further
possible explanation was provided by the post
hoc analysis of drug-naı¨ve versus washout
patients. As observed in patients who
completed the study, drug-naı¨ve patients
showed predicted reductions in their levels of
HbA1c. However, patients entering the study
after the 4-week washout period demonstrated a
negligible change in HbA1c levels. Therefore,
the relatively short washout period in patients
who had already received antidiabetic
monotherapy may have been a second
contributory factor toward this unexpected
finding.
The composite data from this current
exploratory analysis further support the
primary data previously published. In these
data, the alogliptin group demonstrated
considerably fewer hypoglycemic episodes and
as well as significant body weight decreases,
compared with the glipizide group [12]. Indeed,
while there were small but significant weight
reductions observed in the alogliptin group,
weight increases were observed in the glipizide
group [12]. These findings are important,
particularly in older patients who are at risk of
further complications associated with
hypoglycemia.
Although the numbers of patients with a
baseline HbA1c of C8.0% in the alogliptin and
glipizide groups who achieved both composite
endpoints were not significantly different, the
sample sizes were very small, making the
interpretation of results difficult. In addition,
it is possible that patients with higher baseline
HbA1c levels may be less responsive to
treatment and therefore less likely to achieve
HbA1c B7.0% without hypoglycemia or weight
gain.
There are study limitations that warrant
discussion. For example, the titration of
glipizide was limited to 10 mg in this
population of patients. This was due to the age
of the patient population, as older patients are
more at risk of complications, including
hypoglycemia, with higher doses of glipizide.
Limiting the titration avoided any imbalances in
hypoglycemia that could have been attributed
to inappropriately high doses of glipizide in this
older population. Another potential limitation
relates to the post hoc nature of this report; this
type of analysis is an appropriate exploratory
examination of the primary data further
supporting the initial findings, and one that is
often performed after the initial study is
complete. Lastly, although the results from this
study provide important data on the treatment
of older patients with T2DM, interpretation of
the results must be limited to those between the
ages of 65 and 90 years, as per the primary
objective of the study.
Diabetes is a complex disease with many
contributory factors. Treatments that can target
more than one aspect of the condition will offer
patients additional benefits. For example, in a
systematic review and meta-analysis of 53
studies, 17 of which reported endpoint lipid
levels, DPP-4 inhibitors were found to
significantly reduce total cholesterol levels
compared with controls [26]. Other studies
have also demonstrated improvements in lipid
levels with DPP-4 inhibitors [27–32], with these
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agents reportedly being more effective at
reducing lipid levels than alpha glucosidase
inhibitors [32]. Within class differences have
been observed between the DPP-4 inhibitors,
with alogliptin showing a greater reduction in
total cholesterol and LDL levels than sitagliptin
[28]. The efficacy of vildagliptin, sitagliptin and
saxagliptin for reducing lipids varies, with one
study showing vildagliptin to be more effective
at reducing total cholesterol than sitagliptin
and saxagliptin [30], and another showing
vildagliptin to be more effective than
sitagliptin at reducing total cholesterol and
triglycerides [29]. Although further studies are
still required, these differences between and
within drug classes suggest some treatments
may be of more value to certain populations of
patients with T2DM than others, depending on
their characteristics.
Sulfonylureas have been available for many
years and the efficacy, safety and tolerability
profile of this class of drug is well established.
While DPP-4 inhibitors also have a good safety
profile, the recent observation that linagliptin
may result in liver toxicity demonstrates that
additional findings are still being reported with
this newer class of drugs [33]. When considering
the value of individual treatments for different
patient populations, both efficacy and safety
should be considered. For example, elderly
patients often have multiple comorbidities and
although the well-established safety and
tolerability profile of sulfonylureas is beneficial
in this population, the risk of hypoglycemia
with these agents may be of particular concern.
In addition, cost also plays a part in the
treatment decision. Cost is one of the main
disadvantages of DPP-4 inhibitors [34]. This is
particularly true in countries, such as Germany,
where DPP-4 inhibitors are not reimbursed [35].
It is in these situations that value-based
assessments are important. It is possible that,
on balance, in elderly patients who are at high
risk of hypoglycemia and may also have other
comorbid conditions, DPP-4 inhibitors are likely
to offer more value than the sulfonylureas. As
such, more and more focus is being placed on
personalized medicine in older patients with
T2DM, addressing not only glycemic control but
also other factors that might increase morbidity
and mortality in this population [36–40]. In
light of concerns that aggressively lowering
HbA1c may be harmful in older patients with
diabetes, especially those who are frail or have
multiple comorbidities [15, 41], flexible
glycemic targets are more desirable in this
patient group. By examining composite
endpoints that encompass not only indicators
of efficacy but also issues of concern for both
clinicians and patients, such as hypoglycemia
and weight gain, the current analysis attempts
to provide an insight into the overall success of
glycemic control and its adverse effects in older
patients. Such an approach may also offer a way
of differentiating the various treatment options
available for T2DM in older patients. Treatment
options for T2DM are shown to have similar
efficacy in terms of glycemic control; hence,
additional clinical outcomes may add value and
play a more important role. Data such as these
can only help clinicians in getting closer to
achieving a more personalized approach to
T2DM treatment in this high-risk population
of patients.
CONCLUSION
In conclusion, these analyses suggest that, in
older patients aged 65–90 years with T2DM,
alogliptin treatment can achieve a target HbA1c
of B7.0% without hypoglycemia or weight gain
in more patients than glipizide; these results
particularly apply to the subpopulation of
patients with baseline HbA1c below 8.0%.
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